Kornimate/medical-research-clean huggingface dataset:
peppermint oil for the treatment of interstitial cystitis / bladder pain syndrome

Conditions: Interstitial Cystitis

Summary: the purpose of this study is to assess the use of peppermint oil as a treatment for interstitial cystitis/bladder pain syndrome (ic/bps).

after being informed about the study and potential risks, all participants will complete validated ic/bps symptom questionnaires for baseline screening. once participants meet eligibility requirements and give written informed consent they will be randomized in a 1:1 ratio to peppermint oil (200mg tid) or placebo (also tid). participants will complete validated ic/bps questionnaires and follow up surveys over 8 weeks.

Eligibility criteria:
inclusion criteria: * women ages 18-65 years old * diagnosed with ic/bps for at least one month prior to study enrollment exclusion criteria: * culture proven urinary tract infection within 1 month of randomization * gross hematuria * currently pregnant or breastfeeding * unable to speak and read english * history of allergic reaction to peppermint, coconut or enteric coating * history of malabsorption syndrome * history of gastroparesis * history of gastric bypass surgery * history of gastrointestinal, genitourinary or pelvic cancer in the last 5 years * history of insulin dependent diabetes * history of active urinary stone disease

Keywords: interstitial cystitis bladder pain syndrome peppermint
studying a new piece of equipment that can help plan radiation therapy of the spine

Conditions: Thoracic Cancer; Spine Cancer; Thoracic Diseases; Spine Disease; Thoracic Neoplasms; Spine Metastases

Summary: participants will receive an mri with a custom-built mri coil for each participant. the purpose is to find out whether this custom-built mri coil can help doctors see the different parts of the spine as well as or better than they can with standard ct myelograms.


Eligibility criteria:
inclusion criteria: * \>/= 18 years of age at the time of treatment * able to give informed consent * consented for spine stereotactic radiation therapy * no contraindications for ct myelograms which include: * allergy to ct contrast * use of phenothiazines * platelet count \< 60,000 k/mcl * inr \> 1.5 * vegf inhibitor use in the past 2 weeks prior to myelogram * nsaid use in the past 5 days prior to myelogram * renal disease * creatinine \> 1.2 mg/dl * no contraindications for mri scans which include: * newly placed glucose monitors * tattoos (tattoos for radiation therapy are allowed) * presence of a cardiac pacemaker * presence of an implanted cardioverter defibrillator * breast tissue expander * aneurysm clip * any other implanted metallic (bb, bullet, shrapnel, iud, metallic stent or filter, spinal cord simulator etc.) or electronic device which is considered mr unsafe * severe claustrophobia or inability to lie flat for the duration of the study, etc. exclusion criteria: * presence of surgical spine hardware at the region of interest * presence of cervical spine lesions * history of claustrophobia

Keywords: thoracic lesions lumbar lesions sacral spine lesions mri coil spine radiotherapy memorial sloan kettering cancer center 19-476
correlation of pain, obesity and fertility potential.

Conditions: Overweight and Obesity

Summary: the overall aim of the study is to investigate if patients with musculoskeletal chronic pain have reduced semen quality in comparison with age matched healthy controls. secondly, the aim is to investigate whether overweight with or without chronic pain are related to reduced semen quality. we will investigate semen quality in obese chronic pain patients, normal weight chronic pain patients and in obese and normal weight healthy controls.

obesity is associated with several disorders including chronic musculoskeletal pain. for example obesity has been implicated in the development or progression of low back pain and knee osteoarthritis. the mechanism by which obesity causes lumbar back pain is poorly understood, but the contribution of both mechanical and system factors is likely. direct mechanical stress on the intervertebral discs and adjacent structures are suspected to be mechanisms through which obesity affects the spine, leading to subsequent low back pain. the link between obesity and knee osteoarthritis has also been demonstrated, but potential factors underlying the association of obesity with knee osteoarthritis has not entirely been elucidated. it is a well-known fact that obesity leads to an excess load on the joint, increased cartilage turnover, increased collagen type 2 degradation products and increased risk of degenerative meniscal lesions. although all of these factors have been proposed to lead to knee osteoarthritis, no causal relationship has been demonstrated.

Eligibility criteria:
inclusion criteria: * men between 18-45 years with low back pain or knee pain recruited among referees to the orthopaedic outpatient clinics at aalborg university hospital * pain more than 3 months * patients can be on a daily use of paracetamol 1 gram x 4, nsaid x 3-4 or combined * patients will be included regardless of their bmi but will be put in their respective bmi subgroup after the required measurements have been taken * regarding low back pain the lbprs \>9, knee pain the koos \<75 (0-100, i.c. 100 = no problems) * healthy men in the age 18-45 years (matched with enrolled patients) exclusion criteria: * malignancy * ongoing infection * drug addiction defined as the use of cannabis, opioids or other psycho drugs * previous neurologic, musculoskeletal or mental diseases * lack of ability to cooperate * pain rating * patients with a pain rate below 3 * medication * patients taking morphine drugs

Keywords: obesity pain fertility
effectiveness of buspirone and motivational enhancement therapy for the treatment of marijuana dependence - 1

Conditions: Marijuana Abuse; Mood Disorders

Summary: this study will assess the effectiveness of a combination of buspirone and motivational interviewing therapy in the treatment of marijuana dependence.

marijuana dependence is one of the most common substance-related disorders in the united states. despite its prevalence, there is a lack of clinical research addressing treatments for marijuana dependence. research has shown that marijuana abuse is associated with affective disorders. this may be caused by repeated use for relief from anxiety. the use of an anxiolytic agent, a drug that relieves anxiety, may help treat marijuana dependence. motivational enhancement therapy has been shown to reduce marijuana use. therefore, it is likely that buspirone, which is an anxiolytic agent, combined with motivational enhancement therapy will prove beneficial in treating marijuana dependence. this study will assess the effectiveness of a combination of buspirone and motivational interviewing in the treatment of marijuana dependence. this double-blind study will last a total of 16 weeks. participants will be randomly assigned to receive either buspirone or placebo for a period of 12 weeks. there will be one follow-up appointment 4 weeks post-intervention. baseline assessments will include a physical exam and urine and blood tests. study visits will occur weekly throughout treatment in order to monitor compliance, assess adverse affects, and obtain substance use data. mood assessment scales, marijuana craving questionnaires, and a withdrawal symptom checklist will be used to gather the data. urine drug screens will be collected weekly to test for marijuana use. in addition to this, the presence of opioids, cocaine, amphetamines, and benzodiazepines will be tested at baseline, weeks 6 and 12, and at follow-up. a 10-day supply of medication will be dispensed to participants each week. meetings for motivational enhancement therapy will last 30 to 90 minutes each and will occur at baseline, week 2, and week 4. participants' perceived quality of life will be measured at baseline and weeks 6 and 12 to determine the effect of buspirone.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for marijuana dependence * lives within 60 miles of the study site * willing to provide collateral individuals for contact purposes * willing to use an effective form of contraception throughout the study exclusion criteria: * meets dsm-iv criteria for dependence upon a substance other than marijuana, nicotine, or caffeine * meets dsm-iv criteria for a history of schizophrenia or another non-affective psychotic disorder or bipolar disorder * meets dsm-iv criteria for current major depressive disorder or eating disorder * significant cognitive impairment * currently taking benzodiazepines, antidepressant, or antipsychotic medications * major medical illnesses (e.g., hiv, kidney failure, unstable angina, chronic obstructive pulmonary disease, infectious hepatitis) * not in stable housing * pregnant or breastfeeding

Keywords: marijuana mood disorder
diets, metabolic profile and gut microbiota among indonesian women in minangkabau and sundanese-ethnic community

Conditions: Healthy Women; Diet Habit; Bifidobacterium; Inflammation; Obesity; Blood Glucose, High

Summary: many provinces in indonesia have some well known traditional foods that are widely consumed, but it remains unknown whether traditional ethnic dietary patterns can confirm healthy diets. high quality diet is associated with reduced risk of metabolic diseases and modulated gut microbiota. moreover, the relationship between dietary quality and microbiota, a potential mediator of metabolic disease, has not been studied.

this study was conducted in specific villages and hamlets that were randomly selected by multi-stage random cluster sampling in 2 provinces. the investigators randomly selected 36 villages (18 villages in each provinces) by using probability proportional to size cluster sampling to admit the total 360 women who met the criteria and consented. while bifidobacterium, advanced glycation end products (age) and lipid profile were examined in a subgroup of 120 participants from each province (n=240). field enumerators were trained to standardize 24 hours food recall, food frequency questionnaire for 1 month back, and for stool sampling technique procedure. anthropometric measurement was performed by performing weight and height measurement. fasting blood sampling and fecal bifidobacterium examination were done in collaboration with professional laboratories. hemoglobin was assessed by using hemocue. lipid profile was quantified using calorimetric method, fasting blood glucose (fbg) was quantified using enzymatic colorimetric method glucose oxidase - phenol aminophenazone, hba1c was using high performance liquid chromatography (hplc) hexokinase, malondialdehyde level was quantified using will's spectrophotometry, blood advance glycation end products was done by using enzyme linked immunosorbent assay (elisa), carboxymethyl lysine plasma was done by ultra performance liquid chromatography-tandem mass spectometry (uplc-ms/ms), and plasma tumor necrosis factor-alpha was done by elisa. fecal sample were collected in 2 pots, each contain 5-10 gram of stool, and store in cooler box (2-9 degree celcius) until sample was transported to laboratory as soon as possible to store in -80 degree celcius freezer.

Eligibility criteria:
inclusion criteria: * healthy reproductive women aged 19-50 years old * having both parents from the same ethnicities (minangkabau or sundanese) * willing to participate voluntarily signed a written informed-consent. exclusion criteria: * not being pregnant or lactating * not having symptoms of gastrointestinal disturbance such as diarrhea, dysentery, constipation more than 3 days, and/or abdominal pain for the last 2 weeks * not having nausea or vomiting or lost appetite for the last 2 days * no history of malignancy * not consuming antibiotics in the last 1 week before fecal collection * not consuming alcohol more than 3 times a week

Keywords: healthy eating blood glucose bifidobacterium obese women
epic: evaluation of pharmacy-based identification and treatment of hcv

Conditions: Hepatitis C

Summary: the research project aims to understand how pharmacies can be involved in the identification and treatment of hepatitis c (hep c). the study will look at the effectiveness of hep c testing and treatment through pharmacies with support from the cool aid community health centre (cachc). the study will also evaluate the readiness of pharmacies to take on these extra tasks at the pharmacy. this information will be used to develop future strategies to better detect, treat and prevent hep c.

the primary objective of this project is to decrease barriers to care for hepatitis c (hcv) treatment for people who use drugs through the use of rapid diagnostic testing technologies, and task shifting hcv testing and treatment follow up to include trained pharmacy staff. secondary objectives are to evaluate interest, readiness, and effectiveness of community-based pharmacies as a location for the screening and treatment of hcv. a prospective, longitudinal interventional cohort design will be used to enrol people who access community-based pharmacies and have tested for hcv rna. persons with untreated chronic hcv infection will receive direct acting antiviral treatment. this is a trial of pharmacist-led hcv testing and treatment versus conventional care in hcv positive patients.

Eligibility criteria:
inclusion criteria: 1. able to provide informed consent 2. age \> 18 years old 3. documented hcv rna test, interested in being tested for hcv antibody or at risk for hcv (ie. "baby boomers": anyone born between 1945-1965, anyone known to currently (past 6 months) or have a history of injecting drugs, including anyone receiving opiate agonist therapy (oat), any gay or bisexual men who have sex with men (gbmsm)) exclusion criteria: 1) declined to provide informed consent

Keywords: hepatitis c pharmacy testing
comparing high versus low dose of oxytocin, in gravida women with bmi 30 and above which are undergoing induction of labor

Conditions: Induction of Labor; Augmentation of Labor

Summary: the goal of this clinical trial is to compare between higher and lower dose of oxytocin to induce delivery in obese women. researches will compare between low and high doses of oxytocin. the study group will use high dose of oxytocin (20 units in 1000 ml) versus the control group which will use low dose of oxytocin (10 units of oxytocin in 1000 ml)

the duration and the progression of the first stage of labor is slower in obese women and oxytocin seems to be less effective in the treatment of protracted labor in obese women. there is no consensus in the literature about the optimal oxytocin dose. hence, the objective of this study is to compare 2 oxytocin regimens, low vs high dose among obese women who need induction or augmentation of labor. women at term (37-42 weeks), requiring the use of oxytocin for induction of labor or for augmentation of labor. who are obese (bmi 30 and above), viable singleton pregnancies with cephalic presentation. after their consent, will be randomization: in a 1:1 allocation. group 1 (control) will receive a low dose- 10 units of oxytocin in 1000 ml std. starting rate 12 ml/h increase dose by 12 ml/h every 30 min up to 5 contractions / 10 min. max dose 120 ml/h. group 2 (study) will receive a high dose- 20 units of oxytocin in 1000 ml std. starting rate 12 ml/h increase dose by 12 ml/h every 30 min up to 5 contractions / 10 min. max dose 120 ml/h. the primary outcome of the study is the time from the start of oxytocin to delivery statistical analysis mean time interval from initiation of augmentation/ induction with oxytocin until delivery was eight hours (±240 minutes), based on previous observation at the delivery ward. the aim of study is to demonstrate a difference of 2 hours between the 2 groups with an alpha of 0.05 and a power of 80%, a sample size of 64 women per group is required. the primary analysis will be performed on the groups as allocated, that is, by the intention to treat, including all women as randomized.

Eligibility criteria:
inclusion criteria: * women at term (37-42 weeks), requiring the use of oxytocin for induction of labor or for augmentation of labor. * bmi 30 and above * viable singleton pregnancies * cephalic presentation. * no contraindication for vaginal delivery exclusion criteria: * women with previous cesarean delivery * multiple pregnancy * multiple fetal malformations * iufd

Keywords: induction of labor augmentation of labor obese obese gravida high dose of oxytocin in obese gravida
jarvisdhl screening tools

Conditions: Coronary Artery Disease

Summary: the main purpose of this study is to pioneer an easy risk stratification tools, which is developed using novel artificial intelligence (ai) algorithms, that will be able to detect common and fatal heart diseases easily simply through a picture of the back of the eye, the retina. the retinal images will be analysed using a computer application with the risk stratification tool to predict health outcome of individual. the study also aims to correlate between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and clinical outcomes.

cardiovascular disease (cvd) is ranked 1st for mortality rate globally. in 2016, approximately 17.9 million people died from cvds, representing 31% of all global deaths. retinal vasculature has been characterised as the 'window' to the body's circulatory system and been correlated with several diseases that perturbate systemic micro- and macro-vasculature such as hypertension, stroke and chronic kidney disease. as microvascular changes often precede macrovascular changes, retinal imaging has the capability to be an easily available, non-invasive biomarker to screen for multiple vascular pathologies. a deep learning system (dls) is a novel,state-of-art artificial intelligence (ai) technology that has achieved robust diagnostic performance for medical imaging analysis. the integration of deep learning (dl) into retinal image evaluation has accelerated its potential further. its examination of fundus photographs has demonstrated abilities to detect several signs that are undetected by the human eye. with recent correlations being established between cad and retinal vasculature aberrancies such as reduced calibres and fractal dimensions, there is a clear niche for ai to predict cardiac diseases with the use of retinal fundus photographs.

Eligibility criteria:
inclusion criteria for nhcs: 1. 21 years of age or older 2. sufficient language skills in english or chinese 3. provided informed consent 4. completed ctca or ct cac in the past 6 months. inclusion criteria for seri: 1. 21 years of age or older 2. sufficient language skills in english or chinese 3. provided informed consent 4. patient diagnosed with diabetes for more than or equal to 10 years. exclusion criteria for nhcs: 1. patients whose informed consent was not obtained. 2. age \<21 years old 3. patients with cardiac event (acute myocardial infarction, stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (pci) and/or coronary artery bypass grafting (cabg) prior to ctca exclusion criteria in seri:- 1. patient whose informed consent was not obtained. 2. age \<21 years old 3. patients with cardiac event (acute myocardial infarction, stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (pci) and/or coronary artery bypass grafting (cabg) prior to ctca
seven-year outcomes following intensive anti-vegf therapy in wet amd

Conditions: Age-Related Macular Degeneration

Summary: the aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-vegf therapy in patients with exudative amd.

this study was conducted at two clinical sites in budapest, hungary after the "vascular endothelial growth factor (vegf) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (view 2)" phase-3 multicenter, prospective, randomized, double blind clinical trial (clinicaltrials.gov id: nct00637377). patients were treated with intravitreal anti-vegf injections between 2008 and 2017. during the first 2 years in the framework of the view 2 study, participants were randomized per protocol to intravitreal aflibercept or ranibizumab treatment arms and received injections according to the view 2 study protocol. this study focused on long-term outcomes that happened after the view 2 study. after finishing the view 2 study, patients returned to daily routine medical care and were followed under regular clinical care in real-life conditions and were treated with predominantly ranibizumab anti-vegf injections (participants received interventions as part of routine medical care). treatment was administered as needed according to the judgement of the physician. retreatment criteria were based on visual acuity, signs of activity on optical coherence tomography (oct) or indirect slit lamp biomicroscopy. results at the end of the follow-up (year 7) were retrospectively analyzed.

Eligibility criteria:
* same as the original view2 study (nct00637377) * finished view 2 study
home-based nurse intervention in the care of high risk of death patients after discharge from geriatric department

Conditions: Health Services for the Aged; Advance Care Planning

Summary: this study consists to evaluate the feasibility of a case-management intervention of advance care plan (acp) placement for elderly patients at high risk of death at twelve months discharged alive from acute geriatric medicine. feasibility will include the following indicators: rate of patients included and randomized, rate of patients remaining in the study, acp rates achieved at one month.


Eligibility criteria:
inclusion criteria: * patients aged 75 or over. * affiliated to a social security scheme. * hospitalized in an acute care geriatric department * discharged from hospital to home or residential facilities for dependent elderly people * targeted pathology or at least one incurable disease. * at high risk of death in the twelve months following discharge according to the damage prognostic score (high-risk score group). a high risk of death is defined by a damage score \> 50%. * rockwood clinical frailty scale score greater than or equal to 7 at one month. exclusion criteria: * refusal to participate in the study expressed by the patient or his/her legal representative, if applicable. * patients transferred to another medicine-surgery-obstetrics department (only "medicine or surgery" in the elderly). * patients transferred to follow-up care and rehabilitation, palliative care, or returning home in palliative care. * patients who have already drawn up advance directives, chosen a trusted support person or discussed their end-of-life wishes with their doctor. * patients with proven severe neuro-cognitive disorders (in the medical record with a mini-mental state examination (mmse) score below 10 or in the absence of knowledge of the degree of severity and/or a recent previous mmse score taken in a stable period, the referring practitioner, a geriatrician with expertise in this field, will assess whether the patient is unfit to state his or her advance directives at the time of inclusion.

Keywords: elderly advance care plan damage score high risk of mortality discharge from acute care geriatric department